Treatment After Melanoma Surgery Links to Better Survival in Adults 75 and Older
Among 580 older adults, treatment after melanoma surgery was linked to better survival, but the observational study cannot prove cause and effect.
Summary
Drug treatment after melanoma surgery may benefit carefully selected adults aged 75 and older, according to an international study of 580 patients. Researchers compared patients who received treatment after complete removal of advanced melanoma with patients monitored without immediate drug treatment. At five years, melanoma-specific survival was 74% in the treatment group versus 60% in the observation group. Treatment was also linked to better overall survival and longer survival without cancer returning. Among patients monitored without immediate treatment, 69% experienced recurrence, and fewer than half of those received systemic drugs as their first treatment afterward. These findings support discussing treatment options rather than ruling them out based on age alone. However, this retrospective study cannot prove treatment caused better outcomes, and the abstract provides insufficient information about side effects, frailty, or quality of life.
Detailed Summary
Older adults with high risk melanoma often face a difficult choice after surgery whether to start drug treatment or wait and treat the cancer if it returns. Because adults aged 75 and older are underrepresented in trials, evidence about survival benefits in this group remains limited.
Researchers reviewed records from 580 patients aged 75 to 99 whose stage III or IV skin melanoma had been completely removed at 14 international centers. Their median age was 79. After surgery, 222 received immune checkpoint drugs or targeted drugs, while 358 underwent observation. Analyses accounted for age, cancer stage, sex, and mutation status.
At five years, melanoma specific survival was 74% with treatment versus 60% with observation, a 14 percentage point difference. Treatment was associated with a 42% lower adjusted hazard of death from melanoma and a 34% lower adjusted hazard of death from any cause. Survival without cancer recurrence was also better. Among observation patients, 69% experienced recurrence, but only 47% of those received systemic drugs as their first treatment afterward.
These findings support discussing treatment after surgery with carefully selected older patients rather than excluding them because of age alone. However, patients under observation who remained free of recurrence or received drugs after recurrence had no statistically clear difference in melanoma survival compared with treated patients. This selected subgroup comparison does not establish that waiting for recurrence is equally effective.
Because this was a retrospective study, treatment choices may reflect differences in fitness, other illnesses, or clinician judgment that statistical adjustment could not remove. The abstract does not provide detailed side effect, frailty, or quality of life data, making individual benefit versus harm difficult to judge. This summary uses only the abstract and cannot assess the full methods. The results show associations, not proof that treatment caused the observed survival differences.
Key Findings
- Five-year melanoma-specific survival was 74% with treatment after surgery versus 60% with observation, an absolute difference of 14 percentage points.
- Treatment was associated with lower adjusted hazards of melanoma death (HR 0.58) and death from any cause (HR 0.66).
- Recurrence-free survival favored treatment after surgery, with a reported hazard ratio of 0.57.
- Among observation patients, 69% experienced recurrence; only 47% of those received systemic drugs as first-line treatment afterward.
- Discuss postoperative treatment based on individual fitness and preferences; age alone should not determine eligibility.
Methodology
This retrospective cohort study included 580 adults aged at least 75 with completely resected stage III–IV cutaneous melanoma across 14 international centers. It compared anti-PD-1 immunotherapy or BRAF/MEK-targeted therapy with observation, using Kaplan–Meier estimates and Cox regression adjusted for age, stage, sex, and mutation status.
Study Limitations
This summary is based on the abstract only; detailed follow-up, toxicity, frailty, and quality-of-life information could not be assessed. Nonrandomized treatment selection and residual confounding limit causal conclusions, and the selected observation subgroup cannot establish equivalence between immediate and delayed treatment. Multiple authors disclosed pharmaceutical industry relationships.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: